Compare AstraZeneca plc (AZN) vs PPG Industries, Inc. (PPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs PPG Industries, Inc. — how do they compare? AstraZeneca plc trades at $166.4 (market cap $253.13B), while PPG Industries, Inc. trades at $114.66 (market cap $25.56B). The key difference: AstraZeneca plc is far larger — about 9.9× PPG Industries, Inc.'s market cap, and PPG Industries, Inc. pays the higher dividend (2.48%). Which is the better fit depends on your goals.
| AZN | PPG | |
|---|---|---|
Market Cap | $253.13B | $25.56B |
Sector | Health | Basic Materials |
52-Week High | $209.48 | $131.56 |
52-Week Low | $137.44 | $94.34 |
Enterprise Value | $279.37B | $31.66B |
Dividend Yield | 1.92% | 2.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
PPG Industries trades at $113.84, down 2.5% on the day, with a bullish technical signal despite near-term volatility. The stock shows strong profitability with a net margin of 9.83% and ROE of 21.09%, supported by consistent earnings beats in recent quarters. Recent news highlights innovation in aerospace and marine coatings, alongside a sustainable dividend profile. Valuation ratios appear reasonable with a P/E of 16.31 and P/S of 1.6.
The outlook remains positive given analyst consensus favoring a buy rating and a $131.75 price target, implying significant upside. Risks include volume softness and margin pressure, but robust cash flow and strategic innovations provide a cushion. The stock presents a value opportunity with growth catalysts from new product launches and market expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About PPG Industries, Inc.
PPG is a global producer of coatings. The company is the world's largest producer of coatings after the purchase of selected Akzo Nobel assets. PPG's products are sold to a wide variety of end users, including the automotive, aerospace, construction, and industrial markets. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years. PPG is focused on its coatings and specialty products and expansion into emerging regions, as exemplified by the Comex acquisition.
Read more on PPG →
